---
schema_version: "secwatch.filing_event.v1"
accession: "0001588978-22-000003"
form_type: "8-K"
ticker: "PRCT"
cik: "0001588978"
company_name: "PROCEPT BioRobotics Corp"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:03:17.662054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PROCEPT BioRobotics Q3 revenue $20.3M (+135% YoY), raises 2022 guidance to ~$72.5M

## Summary
- Total revenue $20.3M, +135% YoY; US system rev $9.8M (+95%), handpiece $8.0M (+267%).
- Net loss $22.6M vs $14.1M prior year; Adjusted EBITDA loss $18.3M.
- FY2022 revenue guidance raised to ~$72.5M (110% growth) from $66-68M; gross margin 50-51%.
- New $52M five-year loan on Oct 10 retired $50M facility; reduces annual interest ~$2.8M.
- Multi-system national contract with Providence for AquaBeam Robotic Systems announced Sept 19.

## SEC filing metadata
- accession: 0001588978-22-000003
- form_type: 8-K
- ticker: PRCT
- cik: 0001588978
- company_name: PROCEPT BioRobotics Corp
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/0001588978-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/prct-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001588978-22-000003
- JSON: https://secwatch.observer/filing/0001588978-22-000003.json
- Plain text: https://secwatch.observer/filing/0001588978-22-000003.txt

## Key facts
- Earnings Releases
  PROCEPT BioRobotics Corp reported for the quarter ended September 30, 2022 results: revenue $20.3 million. Guidance raised.
  - Period: for the quarter ended September 30, 2022
  - Revenue: $20.3 million
  - Guidance: raised
  - Result: reported results
  source text: care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2022. Recent Highlights • Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year period • U.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/1588978/000158897822000003/0001588978-22-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.